Overview

Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers

Status:
Recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

To verify the role of nab-paclitaxel in second or later-line treatment in advanced biliary tract cancers, the investigators designed a prospective, exploratory, single arm,single center phase II trial, to investigate the efficacy and safety of nab-paclitaxel combined with cisplatin as second or later-line treatment in advanced biliary tract cancers.

Phase:

Phase 2

Details

Lead Sponsor:

Henan Provincial Hospital
Henan Provincial People's Hospital

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel